Hrishikesh Ghanekar, MD
Nephrology · Quincy, ILNPI 1629041686
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Amgen at 28.3% of the total. Reporting peaked in 2019 at $344 and has fallen 60.7% since, to $135 in 2025. That places this record below the midpoint for nephrology clinicians in IL, where the typical reported total is $635.
Across 50 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$238
- Otsuka America Pharmaceutical, Inc.$179
- Vifor Pharma, Inc.$61
- AstraZeneca$58
- Novo Nordisk$44
- Johnson & Johnson$31
- plus $230 from 13 others
Across 16 payments — averaging $3829.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$61K
What the payments were for
- Food & beverage$81697%
- Other$243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $238 |
| Otsuka America Pharmaceutical, Inc. | 11 | $179 |
| Vifor Pharma, Inc. | 4 | $61 |
| AstraZeneca | 2 | $58 |
| Novo Nordisk | 2 | $44 |
| Johnson & Johnson | 2 | $31 |
| Ardelyx, Inc. | 1 | $29 |
| Akebia Therapeutics Inc | 1 | $28 |
| Harmony Biosciences LLC | 1 | $27 |
| Welch Allyn | 2 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $7 |
| Cycle Pharmaceuticals Inc | 1 | $6 |
How this compares
$841 in reported general payments places this provider in the 50th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 243 | $171,464 |
| MounjaroTirzepatide | 68 | $71,856 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $61,378 |
| EliquisApixaban | 103 | $49,007 |
| JardianceEmpagliflozin | 17 | $22,059 |
| XareltoRivaroxaban | 13 | $15,007 |
| TradjentaLinagliptin | 26 | $9,761 |
| ProsolParenteral Amino Acid 20% No.1 | 66 | $9,464 |
| RenvelaSevelamer Carbonate | 16 | $8,506 |
| Potassium Citrate ErPotassium Citrate | 72 | $5,919 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,736 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 198 | $5,183 |
| Calcitriol | 295 | $4,476 |
| Guanfacine Hcl | 85 | $4,100 |
| Potassium Chloride | 164 | $3,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $58 | $171,464243 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $31,82143 claims |
| Johnson & JohnsonXarelto | $31 | $15,00713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 524 nephrology providers in Illinois.
Other nephrology in Quincy
- Myles WolfChicago$2.1M
- Mohammed AhmedBolingbrook$1.1M
- Anis RaufHinsdale$453K
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Suneel UdaniHinsdale$336K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Omaima DeganiGurnee$184K
- Merry DownerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.